Key facts
- This page summarizes Vikas Sinha's Form 4 filing for Allovir, Inc. (KLRS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Apr 2022, 16:25.
Vikas Sinha - 18 Jan 2022 Form 4 Insider Report for Allovir, Inc. (KLRS)
- Reporting relationship
- Officer Title: President and Chief Financial OFficer, Director
- Issuer ticker
- KLRS
- Reported as of
- 18 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Apr 2022, 16:25:06 UTC
- Prior SEC filing
- 10 Aug 2021
- Next SEC filing
- 24 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brett Hagen, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Vikas Sinha filed Form 4 for Allovir, Inc. (KLRS) on 04 Apr 2022.
Change
- Previous filing in this sequence was filed on 10 Aug 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALVR
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +48,838
- Change %
- +5.7%
- Price
- $0.000000
- Shares after
- 907,795
- Date
- 18 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
ALVR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 13,420,970
- Date
- 18 Jan 2022
- Ownership
- See footnote
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALVR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +119,162
- Change %
- Price
- $0.000000
- Shares after
- 119,162
- Date
- 18 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 119,162
- Exercise price
- $9.15
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
Footnote F2
Shares held by ElevateBio LLC ("ElevateBio"). The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Footnote F3
25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
SEC remarks
Officer Title: President and Chief Financial OFficer